RUBY-I: Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with or without Ribavirin in Adults with Genotype 1 Chronic Hepatitis C Virus (HCV) Infection with Severe Renal Impairment or End-Stage Renal Disease

Vierling John M.; Lawitz Eric; Reddy K. Rajender; Cohen Eric; Kemmer Nyingi; Morelli Giuseppe; Zamor Philippe J.; Bennett Michael; Bernstein David E.; Kowdley Kris V.; Mantry Parvez S.; Pockros Paul J.; Wyles David L.; Kumar Sonal; Bhamidimarri Kalyan R.; Cohen Daniel E.; Pilot-Matias Tami; Xie Wangang; Podsadecki Thomas; Hassanein Tarek I.

首页> 外文期刊>Hepatology: Official Journal of the American Association for the Study of Liver Diseases >RUBY-I: Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with or without Ribavirin in Adults with Genotype 1 Chronic Hepatitis C Virus (HCV) Infection with Severe Renal Impairment or End-Stage Renal Disease

【24h】

RUBY-I: Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with or without Ribavirin in Adults with Genotype 1 Chronic Hepatitis C Virus (HCV) Infection with Severe Renal Impairment or End-Stage Renal Disease

机译：Ruby-I：omombitasvir / paritaprevir / ritonavir和dasbuvir的安全性和有效性，或没有利基霉素在成人中，具有基因型1慢性丙型肝炎病毒（HCV）感染严重肾损伤或末期肾病

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Hepatology: Official Journal of the American Association for the Study of Liver Diseases》 |2016年第s1期|共1页
作者
Vierling John M.; Lawitz Eric; Reddy K. Rajender; Cohen Eric; Kemmer Nyingi; Morelli Giuseppe; Zamor Philippe J.; Bennett Michael; Bernstein David E.; Kowdley Kris V.; Mantry Parvez S.; Pockros Paul J.; Wyles David L.; Kumar Sonal; Bhamidimarri Kalyan R.; Cohen Daniel E.; Pilot-Matias Tami; Xie Wangang; Podsadecki Thomas; Hassanein Tarek I.;
展开▼
作者单位

St Lukes Adv Liver Therapies Baylor St Lukes Med Ctr Houston TX USA;

Univ Texas Hlth Sci Ctr San Antonio Texas Liver Inst San Antonio TX 78229 USA;

Univ Penn Philadelphia PA 19104 USA;

AbbVie Inc N Chicago IL USA;

Tampa Gen Med Grp Tampa FL USA;

Univ Florida Hlth Sci Ctr Gainesville FL USA;

Carolinas Med Ctr Charlotte NC 28203 USA;

Med Associates Res Grp San Diego CA USA;

North Shore Univ Hosp Manhasset NY USA;

Swedish Med Ctr Seattle WA USA;

Liver Inst Methodist Dallas Dallas TX USA;

Scripps Clin La Jolla CA 92037 USA;

Univ Calif San Diego La Jolla CA 92093 USA;

Weill Cornell Med Coll New York NY USA;

Univ Miami Miami FL USA;

AbbVie Inc N Chicago IL USA;

AbbVie Inc N Chicago IL USA;

AbbVie Inc N Chicago IL USA;

AbbVie Inc N Chicago IL USA;

Southern Calif GI Ctr Coronado CA USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类消化系及腹部疾病;
关键词

相似文献

外文文献
专利

1. RUBY-I: Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with or without Ribavirin in Adults with Genotype 1 Chronic Hepatitis C Virus (HCV) Infection with Severe Renal Impairment or End-Stage Renal Disease [J] . Vierling John M., Lawitz Eric, Reddy K. Rajender, Hepatology: Official Journal of the American Association for the Study of Liver Diseases . 2016,第S1期

机译：Ruby-I：omombitasvir / paritaprevir / ritonavir和dasbuvir的安全性和有效性，或没有利基霉素在成人中，具有基因型1慢性丙型肝炎病毒（HCV）感染严重肾损伤或末期肾病
2. Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir and Ribavirin Pharmacokinetics in HCV-Infected Subjects with Chronic Kidney Disease Stage 4 (Severe Renal Impairment) or Stage 5 (End-Stage Renal Disease) [J] . Shuster Diana L., Menon Rajeev M., Ding Bifeng, Hepatology: Official Journal of the American Association for the Study of Liver Diseases . 2016,第S1期

机译：HCV感染受试者的ImbItasvir，Paritavir，Ritonavir，Dasabuvir和利巴韦林药代动力学，慢性肾病第4阶段（重肾损伤）或第5阶段（末期肾病）
3. Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir Regimen in the Treatment of Genotype 1 Chronic Hepatitis C Infection in Patients with Severe Renal Impairment and End-Stage Renal Disease: a Real-Life Cohort [J] . Sperl J., Kreidlova M., Merta D., Kidney and blood pressure research . 2018,第2期

机译：Paritaprevir / Ritonavir / Ombitasvir加Dasabuvir方案在严重肾功能不全和终末期肾脏疾病患者的基因型1型慢性丙型肝炎感染中的治疗：一项真实的队列研究
4. Prevalence of autoantibodies and the risk of autoimmune thyroid disease in children with chronic hepatitis C virus (HCV) infection treated with alpha-interferon [C] . S. GEHRING, E. LAUSCH, U. KULLMER, Falk Symposium . 2002

机译：α-干扰素治疗慢性丙型肝炎病毒（HCV）感染儿童自身抗体和自身免疫性甲状腺疾病风险的患病率
5. Population pharmacokinetics and efficacy of ribavirin in patients with chronic hepatitis C genotype 1 infection. [D] . Jin, Runyan. 2010

机译：利巴韦林在慢性丙型肝炎基因型1感染患者中的群体药代动力学和功效。
6. Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in Patients With Chronic Hepatitis C Virus Genotype 1 Infection Receiving Opioid Substitution Therapy: A Post Hoc Analysis of 12 Clinical Trials [O] . Jason Grebely, Massimo Puoti, Heiner Wedemeyer, 2018

机译：Ombitasvir / Paritaprevir / Ritonavir和Dasabuvir联合或不联合利巴韦林在接受阿片类药物替代治疗的慢性丙型肝炎病毒基因型1感染患者中的疗效和安全性：对12项临床试验的事后分析
7. Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir Regimen in the Treatment of Genotype 1 Chronic Hepatitis C Infection in Patients with Severe Renal Impairment and End-Stage Renal Disease: a Real-Life Cohort [O] . Jan Sperl, Miluse Kreidlova, Dusan Merta, 2018

机译：ParitaPrevir / Ritonavir / Obsmitasvir Plus Dasabuvir治疗方法治疗基因型1慢性丙型肝炎患者严重肾损伤和末期肾病患者：真实的队列

RUBY-I: Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with or without Ribavirin in Adults with Genotype 1 Chronic Hepatitis C Virus (HCV) Infection with Severe Renal Impairment or End-Stage Renal Disease

著录项

相似文献

相关主题

期刊订阅